Sangamo Therapeutics, Inc. (NASDAQ:SGMO) Shares Sold by Renaissance Technologies LLC

Renaissance Technologies LLC cut its position in shares of Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) by 36.4% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,084,877 shares of the biopharmaceutical company's stock after selling 1,767,900 shares during the quarter. Renaissance Technologies LLC owned 1.48% of Sangamo Therapeutics worth $3,147,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors have also recently bought and sold shares of the company. Geode Capital Management LLC raised its holdings in shares of Sangamo Therapeutics by 3.4% in the fourth quarter. Geode Capital Management LLC now owns 2,211,849 shares of the biopharmaceutical company's stock worth $2,257,000 after acquiring an additional 73,540 shares during the last quarter. Charles Schwab Investment Management Inc. raised its holdings in shares of Sangamo Therapeutics by 3.3% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 1,139,252 shares of the biopharmaceutical company's stock worth $1,162,000 after acquiring an additional 35,926 shares during the last quarter. State Street Corp grew its position in shares of Sangamo Therapeutics by 28.0% in the third quarter. State Street Corp now owns 664,621 shares of the biopharmaceutical company's stock valued at $576,000 after purchasing an additional 145,400 shares during the period. Golden State Equity Partners grew its position in shares of Sangamo Therapeutics by 2,592.3% in the fourth quarter. Golden State Equity Partners now owns 325,684 shares of the biopharmaceutical company's stock valued at $332,000 after purchasing an additional 313,587 shares during the period. Finally, Virtu Financial LLC purchased a new stake in shares of Sangamo Therapeutics in the third quarter valued at $150,000. 56.93% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

A number of brokerages have recently commented on SGMO. Wells Fargo & Company lowered their price objective on Sangamo Therapeutics from $3.00 to $2.00 and set an "equal weight" rating for the company in a research report on Tuesday, December 31st. Truist Financial lowered their price objective on Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research report on Thursday, January 23rd. HC Wainwright reaffirmed a "buy" rating and issued a $10.00 price objective on shares of Sangamo Therapeutics in a research report on Monday, April 7th. Jefferies Financial Group cut their price objective on Sangamo Therapeutics from $7.00 to $3.00 and set a "buy" rating on the stock in a report on Tuesday, December 31st. Finally, Royal Bank of Canada reiterated a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a report on Tuesday, March 18th. Three investment analysts have rated the stock with a hold rating and four have issued a buy rating to the stock. According to MarketBeat, Sangamo Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $5.17.

Sangamo Therapeutics Stock Down 3.0 %

Shares of SGMO traded down $0.02 during mid-day trading on Tuesday, reaching $0.72. 748,227 shares of the stock traded hands, compared to its average volume of 8,502,067. The firm has a market cap of $161.34 million, a price-to-earnings ratio of -0.96 and a beta of 1.57. The stock has a fifty day simple moving average of $0.83 and a 200 day simple moving average of $1.38. Sangamo Therapeutics, Inc. has a 12-month low of $0.30 and a 12-month high of $3.18.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its quarterly earnings results on Monday, March 17th. The biopharmaceutical company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.09) by ($0.02). Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%. The company had revenue of $7.55 million during the quarter, compared to the consensus estimate of $11.70 million. On average, equities research analysts expect that Sangamo Therapeutics, Inc. will post -0.46 earnings per share for the current fiscal year.

Sangamo Therapeutics Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.